Aptus Pharma Ltd Approves Multi-Crore Fund Raising for Business Expansion

Aptus Pharma Ltd Approves Multi-Crore Fund Raising for Business Expansion​

Aptus Pharma Limited has approved a proposal to raise funds up to 51 Crores for the expansion of its business operations. The decision was made by the Board of Directors during a meeting held on June 12, 2026.

The fund raising aims to support the company's growth and expansion activities. The aggregate amount sanctioned includes allocations through preferential allotment, debt financing, and internal accruals.

Fund Raising Structure Details

The approved funding structure is detailed as follows:


The company stated that the proposed preferential allotment will be executed in accordance with applicable laws and regulations. The terms and conditions of this fund raising, including the nature of securities, issue price, and identified investors, are subject to future determination by the Board or a designated committee.

Managing Director Delegates Authority

In connection with the Proposed Preferential Allotment, the Board of Directors authorized Mr. Tejas Hathi, Managing Director, to undertake specific activities. These authorities include identifying prospective investors, conducting due diligence, and negotiating terms for the allotment.

Mr. Hathi is also tasked with collecting necessary information and documents from the proposed allottees before placing a comprehensive report before the Board at a subsequent meeting for final consideration and approval. The delegation of authority is currently limited to identification, evaluation, and interaction. Final approval of the Preferred Allotment, including setting the issue price and determining the identity of the allottee(s), must be secured by the Board at a future meeting.

Status of Transaction

The company clarified that the resolutions passed during the Board Meeting are enabling and represent the maximum ceiling for fund raising and the delegation of identification authority. The specific details relating to the Proposed Preferential Allotment, such as the issue price, the number of securities, and the identity of the proposed allottees, have not been finalized at this stage.

Aptus Pharma Limited confirmed that the approval of shareholders through a Special Resolution at an Extraordinary General Meeting (EGM) or Annual General Meeting (AGM), along with other required regulatory approvals, must be obtained before the Preferred Preferential Allotment can be given effect.

Stock Price Movement​

At the close of trade on Friday, Aptus Pharma Ltd. settled at ₹216.10, after slipping 2.00% from previous closing prices. The shares remained completely locked, trading flat throughout the entire session.